Corporate Governance Principles
Lioness Medtech AB (publ) follows a high-standard governance structure designed to ensure accountability, transparency, responsible decision-making and long-term value creation for shareholders. The Board follows rules of procedure aligned with the Swedish Corporate Governance Code (Svensk kod för bolagsstyrning).

Governance Structure
Lioness Medtech AB (publ)’s  governance framework defines the roles of the General Meeting, Board of Directors, CEO and auditor. Annual reviews are conducted to ensure the structure supports strategic execution, risk management and sustainable value creation.

Decision-Making Framework
Lioness Medtech AB (publ) has formal procedures for decision-making at Board and management levels, including instructions for the CEO, rules of procedure for the Board and financial reporting routines. The Board and management combine extensive experience in medical technology, international business development, and financial management. The collective background ensures strategic control and operational excellence as the company expands in the European radiopharma and advanced med-tech markets.

Sustainability Integration
ESG considerations are integrated into Lioness Medtech AB (publ)’s  governance practices. The Board oversees environmental and social impact within strategic planning, supplier selection and long-term investment priorities.

Environmental, Social and Governance (ESG)
Lioness Medtech AB (publ) is committed to responsible and sustainable business practices throughout its operations. As a provider of advanced medical-technology solutions and radiopharma infrastructure, the company actively supports healthcare systems in improving patient outcomes while maintaining high ethical, environmental and social standards.

Environmental Responsibility
Lioness Medtech AB (publ) operates under a certified environmental management system (ISO 14001) and a certified quality system (ISO 9001), ensuring structured and measurable environmental performance. The company works to reduce resource consumption, improve waste handling, and minimise the environmental footprint associated with transportation, service operations and equipment deliveries.

Social Commitment
Lioness Medtech AB (publ) follows a Code of Conduct that promotes fair working conditions, equality, diversity and zero tolerance for discrimination or corruption. The company collaborates closely with hospitals, research institutions and partners to support safe clinical environments, education, and long-term competence development.

Governance and CSR
The Board of Directors oversees risk management, regulatory compliance, ethical business conduct, and data protection (GDPR). Sustainability and governance performance are reviewed annually and reported transparently to shareholders.

Compliance and Legal Framework
Lioness Medtech AB (publ) applies a structured compliance framework to ensure responsible, transparent and legally sound operations. The company follows applicable EU and Swedish legislation, including the Swedish Companies Act, MAR (Market Abuse Regulation), GDPR, and sector-specific regulations for medical-technology products.

Code of Conduct / Ethics
Lioness Medtech AB (publ) operates under a Code of Conduct based on integrity, accountability and professionalism. It outlines expectations for employees, partners and suppliers regarding ethical behaviour, anti-corruption, fair competition and compliance with international med-tech industry standards.

GDPR, Privacy & Whistleblower Policy
Lioness Medtech AB (publ) complies with GDPR and maintains internal routines for the secure handling of personal data. A whistleblower mechanism is available for reporting suspected misconduct, guaranteeing confidentiality and protection from retaliation.

Shareholder Information Overview
Lioness Medtech AB (publ) provides timely, factual and transparent information to all shareholders to support well-founded investment decisions. The company is committed to equal treatment of all investors and communicates significant events through press releases, regulatory announcements and financial reporting.

Major Shareholders
Ownership is anchored by the founding team and long-term shareholders, ensuring stability and strategic continuity. Updated ownership information is published regularly in connection with reporting.

Pharos PET System

Brightonix Imaging is a medical imaging company headquartered in Korea, established with the goal of providing society with innovative biomedical imaging devices and AI solutions. Brightonix specializes in advanced medical imaging technologies, combining intelligent software with compact, high-performance imaging systems. Brightonix’s key portfolio includes medical imaging AI solutions and compact platforms such as SimPET, designed for simultaneous PET/MRI studies in small animals, and the Pharos PET scanner, a compact PET imaging system developed to deliver high image quality and efficient workflow for research and preclinical applications.

Brightonix’s mission is to empower clinicians and researchers with intelligent imaging technologies that improve diagnostic confidence, procedural accuracy, and clinical outcomes, bringing high-quality, accessible imaging to hospitals, research institutions, and care centers worldwide.